心力衰竭患者地高辛血药浓度监测结果与临床疗效分析

目的：探讨慢性心力衰竭患者地高辛血药浓度与临床疗效的关系。方法：采用荧光偏振免疫法（FPIA）测定337例地高辛血药浓度,根据地高辛血药浓度将患者分成5组,并分析其临床资料。结果：A组（〈0.50ng·mL-1）患者的有效率、全因住院率、全因死亡率及中毒率分别为18.8%、27.5%、11.6%、0.0%;B组（0.50～0.90ng·mL-1）患者分别为85.3%、26.3%、13.7%0.0%;C组（0.91～1.50ng·mL-1）患者分别为87.3%、31.6%、19.0%、3.8%;D组（1.51～2.00ng·mL-1）患者分别为84.8%42.4%、24.2%、12.1%;E组（〉2.00ng·mL-1）患者分别为44.3%、59.0%、36.1%、54.1%。结论：地高辛治疗慢性心力衰竭的血药浓度以0.50～0.90ng·mL-1为宜。

Analysis of Serum Digoxin Concentration and Clinical Efficacy in Patients with Heart Failure

OBJECTIVE：To investigate the relationship between serum concentration of digoxin and clinical efficacy in patients with heart failure.METHODS：The serum concentration of digoxin in 337 patients was determined by fluorescent polarization immunoassay （ FPIA）.The patients were divided into five groups according to the serum concentration of digoxin with their clinical data analyzed.RESULTS：The effective rate,all-cause hospitalization rate,all-cause mortality rate and rate of poisoning by digoxin in group A （0.50 ng·mL-1） were 18.8% ,27.5% , 11.6% and 0.0% ,respectively,as compared with 85.3% ,26.3% ,13.7% and 0.0% ,respectively in group B （0.50-0.90 ng·mL-1）,87.3% ,31.6% ,19.0% and 3.8% ,respectively in group C （0.91-1.50 ng·mL-1）, 84.8% ,42.4% ,24.2% ,12.1% ,respectively in group D （1.51-2.00 ng·mL-1 ）,and 44.3% ,59.0% , 36.1% and 54.1% ,respectively in group E （2.00 ng·mL-1 ）.CONCLUSION：The optimal serum concentration range of digoxin is 0.50-0.90 ng·mL-1 in the treatment of chronic heart failure.